Amyloidosis from pathology point of. view

Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Loading Image
Reading File
Loading Image
Reading File
I now have comprehensive, detailed content from Robbins & Kumar. Let me compile this into a thorough pathology-focused answer.

Amyloidosis: A Pathology Perspective

Based primarily on Robbins, Cotran & Kumar - Pathologic Basis of Disease

Definition

Amyloidosis is not a single disease but a group of disorders in which proteins with the propensity to aggregate form insoluble fibrils that deposit in extracellular tissues, causing disruption of tissue architecture and functional compromise. The deposits bind proteoglycans and glycosaminoglycans (heparan sulfate, dermatan sulfate) and plasma proteins, particularly serum amyloid P-component (SAP). The name "amyloid" derives from a historical resemblance to starch (amylose) because of iodine staining - a misnomer since the material is protein, not polysaccharide.

Physical Nature of Amyloid

By electron microscopy, all amyloid - regardless of clinical setting or chemical composition - consists of:
  • Continuous, nonbranching fibrils, approximately 8-10 nm in diameter
  • Each fibril made up of stacks of protofilaments arranged in a beta-pleated sheet (cross-β) conformation
This beta-pleated sheet configuration is shared by all amyloid types and is directly responsible for the characteristic Congo red staining and birefringence.
Chemical composition: ~95% fibril proteins + ~5% serum amyloid P and other glycoproteins.
Mechanism of amyloid deposition: misfolded proteins oligomerize into fibrils that deposit extracellularly, disrupting tissue architecture
Fig. 6.44 - Mechanism of amyloid deposition (Robbins)

Classification and Pathogenesis

Over 40 different proteins can form amyloid. The three most common forms are:

1. AL Amyloidosis (Amyloid Light Chain)

  • Protein source: Monoclonal immunoglobulin light chains (usually lambda > kappa), produced by a clonal plasma cell population
  • Clinical setting: Multiple myeloma, other plasma cell dyscrasias, sometimes without overt malignancy (primary amyloidosis)
  • Most common systemic form overall
  • Preferentially involves: heart, GI tract, respiratory tract, peripheral nerves, skin, tongue

2. AA Amyloidosis (Amyloid-Associated)

  • Protein source: Serum amyloid A (SAA), an acute-phase protein synthesized by the liver; proteolytically cleaved to form AA fibrils
  • Clinical setting: Chronic inflammatory states - rheumatoid arthritis, inflammatory bowel disease, familial Mediterranean fever, chronic infections (TB, osteomyelitis, bronchiectasis), certain cancers
  • Preferentially involves: kidneys, liver, spleen, lymph nodes, adrenals, thyroid

3. ATTR Amyloidosis (Transthyretin)

  • Protein source: Transthyretin (TTR), a plasma protein that transports thyroxine and retinol
    • ATTRwt (wild-type): Normal TTR aggregates; occurs in males >70 years; cardiac predominance - "senile cardiac amyloidosis"; increasingly prevalent with aging population
    • ATTRv (variant/hereditary): Mutant TTR; familial; deposits in heart, peripheral nerves, and other tissues

Other Forms

ProteinFibril NameSetting
Aβ peptide (from APP)Alzheimer disease (cerebral plaques + vessel walls)
β2-microglobulin (MHC I component)Aβ2mLong-term hemodialysis - carpal tunnel, joints
Misfolded prion proteinsPrion amyloidPrion diseases (CNS)
Calcitonin precursorACalMedullary thyroid carcinoma (local)
InsulinA-insulinType 2 diabetes (islets of Langerhans)
Pathogenic mechanism: Amyloidogenic proteins arise by two mechanisms:
  1. Normal proteins that have an inherent tendency to misfold when produced in excess or when degradation is impaired (SAA in AA; wild-type TTR in ATTRwt)
  2. Variant (mutant) proteins that are structurally prone to misfolding (mutant TTR in ATTRv)
Quality-control failure - both intracellular (proteasomal) and extracellular (macrophage-mediated degradation) - allows accumulation of misfolded proteins.

Histopathology and Staining

Light Microscopy (H&E)

Amyloid deposits appear as amorphous, eosinophilic, hyaline, extracellular material - identical in appearance to collagen or fibrin on routine staining alone.

Congo Red Stain (Diagnostic Gold Standard)

  • Under ordinary light: Pink-red deposits
  • Under polarized light: Characteristic apple-green birefringence
  • This reaction is shared by all forms of amyloid and is conferred by the cross-beta pleated fibril configuration

Other Stains

  • Crystal violet / methyl violet: Metachromatic staining (purple-red color)
  • Thioflavin T/S: Fluorescent staining - bright yellow-green fluorescence under UV (very sensitive, used for frozen sections)
  • PAS: Weakly positive, diastase-resistant
  • Electron microscopy: Amorphous nonoriented thin fibrils

Specific Typing

  • Immunohistochemistry (IHC): Specific antibodies against AA, AL (kappa/lambda light chains), ATTR - required for subtyping
  • Mass spectrometry (laser capture + LC-MS/MS): Emerging gold standard for typing, especially when IHC fails
Amyloidosis histology: A) Congo red stain in liver sinusoids; B) Apple-green birefringence under polarized light; C) Obliteration of renal glomerulus by amyloid deposits
Fig. 6.46 - Amyloidosis (A) Congo red stain in liver, (B) apple-green birefringence under polarized light, (C) massive amyloid obliteration of glomerulus (Robbins)

Morphology by Organ

Gross Appearance

When substantial: enlarged organ, gray, waxy, firm consistency ("lardaceous" organs - from Latin for lard).

Kidney (most common + most serious)

  • Early: Subtle mesangial matrix thickening + uneven widening of glomerular basement membranes
  • Progressive: Capillary narrowing and distortion of the glomerular vascular tuft
  • Advanced: Capillary lumens obliterated; glomerulus flooded by confluent masses of amyloid - "obsolescent glomerulus"
  • Interstitium, arteries, and arterioles also involved
  • Grossly: normal size or shrunken (from ischemia due to vascular amyloid deposition)

Spleen

Two classic patterns:
  • Sago spleen: Deposits limited to splenic follicles; tapioca-like granules on gross inspection
  • Lardaceous spleen: Deposits in sinus walls and red pulp connective tissue; large maplike areas; marked splenomegaly (up to 800 g)

Liver

  • May be inapparent to massively enlarged
  • Deposits begin in space of Disse (between sinusoidal endothelium and hepatocytes)
  • Progress to compress hepatic parenchyma
  • Portal tracts and hepatic vessels also affected in advanced disease

Heart

  • May be enlarged and firm, or no gross change
  • Subendocardial focal deposits initially, then between myocardial fibers
  • Expansion causes pressure atrophy of myofibers
  • Subendocardial deposits damage the conduction system - arrhythmias, heart block
  • Produces restrictive cardiomyopathy pattern

Tongue and GI Tract

  • Macroglossia: Nodular deposits causing tongue enlargement; characteristic of AL amyloid
  • Stomach/intestine: malabsorption, diarrhea
  • Vascular fragility: spontaneous or traumatic bleeding; factor X inactivation by AL amyloid causes coagulopathy

Nervous System

  • Peripheral and autonomic neuropathies (hereditary ATTR amyloidosis)
  • Carpal tunnel syndrome (bilateral) - classic feature of β2-microglobulin amyloidosis (hemodialysis patients)
  • Alzheimer disease: cerebral plaques (senile plaques) + cerebrovascular amyloid angiopathy

Adrenals, Thyroid, Pituitary

  • Involved in generalized secondary (AA) amyloidosis

Clinical Features

The clinical manifestations depend on the magnitude of deposits and organs affected. Onset is insidious.
SystemClinical Manifestations
RenalProteinuria → nephrotic syndrome → progressive renal failure → uremia (common cause of death)
CardiacRestrictive cardiomyopathy, congestive heart failure, arrhythmias/heart block (can be fatal)
GIMacroglossia, malabsorption, diarrhea, GI bleeding
VascularVascular fragility, bleeding; factor X deficiency (AL) → life-threatening coagulopathy
NeurologicPeripheral neuropathy, autonomic neuropathy, carpal tunnel syndrome
ConstitutionalWeakness, weight loss, lightheadedness, syncope (early and nonspecific)

Diagnosis

  • Biopsy is required for histologic confirmation
  • Common biopsy sites:
    • Abdominal fat pad aspiration - simple, minimally invasive, ~80% sensitivity in AL/AA
    • Rectal biopsy - submucosa sampled
    • Kidney - when renal manifestations predominate
    • Bone marrow - often positive in AL
    • Organ-specific biopsy if above negative but suspicion remains
  • SAP scintigraphy (radiolabeled serum amyloid P scan) - whole-body imaging of amyloid burden (not widely available)
  • Serum/urine immunofixation + free light chain assay - screening for AL
  • Genetic testing - for ATTR variant mutations

Summary Table: Key Amyloid Types

TypeFibril ProteinPrecursorClinical Setting
ALLight chains (λ > κ)Immunoglobulins (plasma cells)Myeloma, plasma cell dyscrasia, primary
AAAA proteinSAA (liver, acute-phase)Chronic inflammation (RA, IBD, TB, FMF)
ATTRwtWild-type TTRTTRSenile cardiac (males >70)
ATTRvVariant TTRMutant TTR geneHereditary (FAP, cardiac ATTR)
β-amyloidAPP (amyloid precursor protein)Alzheimer disease
Aβ2mβ2-microglobulinMHC-I componentHemodialysis (carpal tunnel, joints)

Reference: Robbins, Cotran & Kumar - Pathologic Basis of Disease, Chapter 6 (Diseases of the Immune System), Amyloidosis section, pp. 246-251.
This is a shared conversation. Sign in to Orris to start your own chat.